Home > Insider Trading > Filing (0001209191-21-021556)

Filing Details

Accession Number:: 0001209191-21-021556
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-03-17 19:09:06
Reporting Period:: 2021-03-15

Accepted Time:: 2021-03-17 19:09:06
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1679363	Morphic Holding Inc.	MORF	Pharmaceutical Preparations (2834)	473878772

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1780273	Bruce Rogers	C/O Morphic Holding, Inc. 35 Gatehouse Drive, A2 Waltham MA 02451	Chief Scientific Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2021-03-15	2,900	$63.97	95,458	No	4	S	Direct
Common Stock	Disposition	2021-03-15	1,345	$64.83	94,113	No	4	S	Direct
Common Stock	Disposition	2021-03-15	1,341	$66.04	92,772	No	4	S	Direct
Common Stock	Disposition	2021-03-15	1,693	$66.86	91,079	No	4	S	Direct
Common Stock	Disposition	2021-03-15	1,030	$67.85	90,049	No	4	S	Direct
Common Stock	Disposition	2021-03-15	200	$69.21	89,849	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Footnotes

The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.35 to $64.34 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Includes 744 shares of Common Stock acquired under the issuer's employee stock purchase plan on February 26, 2021.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.35 to $65.32 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.40 to $66.32 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.41 to $67.27 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.42 to $68.35 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.